Sarepta Signs a Research Agreement with the US Department of Defense to Identify Antisense Oligonucleotides Against COVID-19

 Sarepta Signs a Research Agreement with the US Department of Defense to Identify Antisense Oligonucleotides Against COVID-19

Sarepta Signs a Research Agreement with the US Department of Defense to Identify Antisense Oligonucleotides Against COVID-19

Shots:

  • Sarepta and USAMRIID have entered into a CRADA to jointly identify antisense oligonucleotides utilizing Sarepta’s phosphorodiamidate morpholino oligomer (PMO) platform with activity against SARS-CoV-2 for the potential treatment of COVID-19
  • Sarepta will design, synthesize and manufacture multiple peptide-conjugated PMO (PPMO) constructs based on genetic sequencing of SARS-CoV-2 while USAMRIID will assess the constructs on characterized wild-type SARS-CoV-2 viruses for their potential to inhibit viral infection
  • Following the results, Sarepta and USAMRIID will contemplate collaborative funding proposals to advance the development of treatments against COVID-19

Click here ­to­ read full press release/ article | Ref: Sarepta | Image: Sarepta

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post